OA21.06 ctDNA Dynamics, Prognostic Markers and Resistance Mechanisms in Tepotinib-Treated METex14 Skipping NSCLC in the VISION Trial

X. Le, M.C. Garassino,M.-J. Ahn,E. Felip, A.B. Cortot,H. Sakai,J. Mazieres, M. Thomas,S. Viteri, P. Conte,J.C.-H. Yang,W.T. Iams,F. Griesinger,C. Stroh,D. Juraeva,D. Wang,A. Johne,P.K. Paik

Journal of Thoracic Oncology（2023）

引用 0|浏览3

暂无评分

摘要

Tepotinib showed robust and durable efficacy in NSCLC with MET exon 14 skipping (METex14). Liquid biopsy (LBx) biomarkers (NGS and circulating MET-related markers) were analyzed for potential prognostic, predictive, or pharmacodynamic relevance (data cut-off: Nov 20, 2022).

查看译文

关键词

metex14 skipping nsclc,ctdna,prognostic markers,tepotinib-treated

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要